A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors

Sponsor

GI Innovation, Inc. (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05824975

Collaborator

(none)

Enrollment

Locations

Arms

26.6

Anticipated Duration (Months)

Patients Per Site

0.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent over a range of advanced and/or metastatic solid tumors.

Condition or Disease	Intervention/Treatment	Phase
Advanced Solid Tumor Metastatic Solid Tumor	Drug: GI-102 Drug: GI-102	Phase 1/Phase 2

Detailed Description

This is a phase 1/2a, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, and anti-tumor effect of GI-102 as a single agent over a range of advanced and/or metastatic solid tumors. This study is adaptive in nature. While GI-102 is being investigated as a single agent in this trial, GI-102 has the potential of being combined with other agents. Based on the data from ongoing nonclinical studies and the dose escalation phase, additional combination therapies [GI-102 + drug(s) X] may be proposed and added to this study protocol via an amendment.

This study will comprise two phases.

GI-102 monotherapy dose escalation phase
GI-102 monotherapy dose expansion phase

GI-102 is a novel bi-specific Fc fusion protein containing the CD80 ectodomain as an N-terminal moiety and an interleukin (IL)-2 variant as a C-terminal moiety configurated via a human immunoglobulin G4 (IgG4) Fc. GI-102 has unique characteristics by having bispecificity to CD80 and IL2Rβγ. The CD80 portion is responsible for targeting tumor/immune cells while blocking CTLA-4 expressed on the Treg cells. The IL-2v of GI-102 is designed to abolish IL-2Rα affinity and therefore minimize the effect on Treg while it has very outstanding effect on NK and CD8 T cell proliferation and activity through IL-2Rbr affinity.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

92 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2a Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Therapeutic Activity of GI-102 in Patients With Advanced or Metastatic Solid Tumors

Anticipated Study Start Date :

Apr 12, 2023

Anticipated Primary Completion Date :

Apr 30, 2025

Anticipated Study Completion Date :

Jun 30, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Dose escalation phase : GI-102 as a single agent Dose escalation: GI-102, multiple ascending doses	Drug: GI-102 Dose escalation phase: GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 cycles).
Experimental: Dose expansion phase : GI-102 as a single agent Dose expansion: GI-102, tentative RP2D	Drug: GI-102 Dose expansion phase: GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 cycles).

Arm

Intervention/Treatment

Experimental: Dose escalation phase : GI-102 as a single agent

Dose escalation: GI-102, multiple ascending doses

Drug: GI-102

Dose escalation phase: GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 cycles).

Experimental: Dose expansion phase : GI-102 as a single agent

Dose expansion: GI-102, tentative RP2D

Drug: GI-102

Dose expansion phase: GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 cycles).

Outcome Measures

Primary Outcome Measures

Incidence and nature of Dose-Limiting Toxicity (DLTs) (dose escalation phase) [Study Day 1, assessed up to DLT period (3 weeks after treatment)]
A DLT is defined as a clinically significant AE (classified according to the NCI CTCAE version 5) or significant laboratory abnormality that occur during the DLT assessment periods, during dose escalation and dose expansion, and is considered by the Investigator to be related to GI-102.
Incidence, nature, and severity of adverse events (AEs) and immune-related AEs (irAEs) (dose escalation phase) [Study Day 1, assessed up to approximately 24 months]
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. All AE events will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Objective Response Rate (ORR) (dose expansion phase) [Study Day 1, assessed up to approximately 24 months]
ORR is defined as the percentage of participants with investigator-assessed objective response of complete response (CR) or partial response (PR). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions).

Secondary Outcome Measures

Incidence and nature of Dose-Limiting Toxicity (DLTs) (dose expansion phase) [Study Day 1, assessed up to DLT period (3 weeks after treatment)]
A DLT is defined as a clinically significant AE (classified according to the NCI CTCAE version 5) or significant laboratory abnormality that occur during the DLT assessment periods, during dose escalation and dose expansion, and is considered by the Investigator to be related to GI-102.
Objective Response Rate (ORR) (dose escalation phase) [Study Day 1, assessed up to approximately 24 months]
ORR is defined as the percentage of participants with investigator-assessed objective response of complete response (CR) or partial response (PR). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions).
Disease Control Rate (DCR) [Study Day 1, assessed up to approximately 24 months]
DCR is defined as the percentage of patients who have achieved CR, PR and stable disease (SD), per RECIST v1.1 guideline as determined by the investigators.
Duration of objective response (DoR) [Study Day 1, assessed up to approximately 24 months]
DCR is defined as the time from the first occurrence of a documented objective response to the time of the first document disease progression or death from any cause, whichever occurs first, per RECIST v1.1 as determined by the investigator.
Progression-free survival (PFS) [6-month, 12-month, and 18-month]
PFS is defined as the time from the first study treatment (Day 1) to the first occurrence of progression or death from any cause, whichever occurs first, per RECIST v1.1 guideline as determined by the investigator
Overall survival (OS) [12-month and 18-month]
OS is defined as the time from the first study treatment to death from any cause
Peak plasma concentration (Cmax) of GI-102 [Study Day 1, assessed up to approximately 24 months]
Based on the concentration vs time profile by dose level
Half-life of GI-102 (T1/2) [Study Day 1, assessed up to approximately 24 months]
Based on the concentration vs time profile by dose level
Area under the plasma concentration versus time curve (AUC) of GI-102 [Study Day 1, assessed up to approximately 24 months]
Based on the concentration vs time profile by dose level
Clearance of GI-102 [Study Day 1, assessed up to approximately 24 months]
Based on the concentration vs time profile by dose level
Volume of distribution (Vd) of GI-102 after administration [Study Day 1, assessed up to approximately 24 months]
Based on the concentration vs time profile by dose level

Other Outcome Measures

Incidence of anti-GI-102 antibody (ADA) and neutralizing antibody (Nab) [Study Day 1, assessed up to approximately 24 months]
Serum will be assessed for the presence of ADA and Nab based on the appropriate assay.
Immunophenotyping of peripheral blood CD4+ T cells [Study Day 1, assessed up to approximately 24 months]
CD4+ T cells in peripheral blood will be assessed by flow cytometry at various time points
Immunophenotyping of peripheral blood CD8+ T cells [Study Day 1, assessed up to approximately 24 months]
CD8+ T cells in peripheral blood will be assessed by flow cytometry at various time points
Immunophenotyping of peripheral blood Treg cells [Study Day 1, assessed up to approximately 24 months]
Treg cells in peripheral blood will be assessed by flow cytometry at various time points

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Key Inclusion Criteria:

Males and females aged ≥ 18 years (or ≥ 19 years according to local regulatory guidelines) at the time of screening.
Has adequate organ and marrow function as defined in protocol.
Measurable disease as per RECIST v1.1.
ECOG performance status 0-1.
Adverse events related to any prior chemotherapy, radiotherapy, immunotherapy, other prior systemic anti-cancer therapy, or surgery must have resolved to Grade ≤1, except alopecia and Grade 2 peripheral neuropathy.
HIV infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease as defined in protocol.

Key Exclusion Criteria:

Has known active CNS metastases and/or carcinomatous meningitis.
An active second malignancy.
Has active or a known history of Hepatitis B or known active Hepatitis C virus infection.
Has active tuberculosis or has a known history of active tuberculosis.
Active or uncontrolled infections, or severe infection within 4 weeks before study treatment administration.
History of chronic liver disease or evidence of hepatic cirrhosis, except patients with liver metastasis.
Has an active autoimmune disease that has required systemic treatment in past 2 years.
Previous immunotherapies related to mode of action of GI-102.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive medications within 2 weeks prior to Cycle 1 Day

Administration of prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment.
Radiotherapy within the last 2 weeks before start of study treatment administration, with exception of limited field palliative radiotherapy.
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1.
Known hypersensitivity to any of the components of the drug products and/or excipients of GI-102.

Other protocol defined inclusion exclusion criteria may apply

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Yonsei University Health System, Severance Hospital	Seoul	Korea, Republic of	03722
2	Yonsei University Health System, Severance Hospital	Seoul	Korea, Republic of	03722
3	Asan Medical Center	Seoul	Korea, Republic of	05505
4	Samsung Medical Center	Seoul	Korea, Republic of	06351